Clinical Trials
69
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (46 trials with phase data)• Click on a phase to view related trials
Study of Vascular Function Before vs After Smoking an E-cigarette as Compared to a Normal Cigarette
- Conditions
- Endothelial Function
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 64
- Registration Number
- NCT05598125
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 70
- Registration Number
- NCT05181592
- Locations
- 🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria
🇦🇹Medizinische Universität Wien, Vienna, Austria
🇩🇪OncoResearch Lerchenfeld GmbH, Hamburg, Germany
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
- Conditions
- Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 306
- Registration Number
- NCT04833114
- Locations
- 🇦🇹
UK Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie, Graz, Austria
🇦🇹LKH Hochsteiermark Standort Leoben Abteilung für Innere Medizin Department für Hämato-Onkologie, Leoben, Austria
🇦🇹Ordensklinikum Linz GmbH- Elisabethinen: I. Interne Abteilung Hämato-Onkologie, Linz, Austria
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
- Conditions
- Pancreatic AdenocarcinomaPancreas CancerPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT04257448
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪Universitätsklinikum Frankfurt, Frankfurt, Germany
🇩🇪Universitätsmedizin Göttingen, Göttingen, Germany
Emicizumab in Acquired Hemophilia A
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 47
- Registration Number
- NCT04188639
- Locations
- 🇦🇹
Medizinische Universität Wien, Hämatologie/Hämostaseologie, Wien, Niederösterreich, Austria
🇦🇹Medizinische Universitätsklinik Graz, Graz, Steiermark, Austria
🇦🇹Landeskrankenhaus Salzburg, Universitätsklinikum der PMU, Innere Med. III, Salzburg, Austria
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next